Immunocytochemical expression of Ki-67/p16 in normal, atypical, and neoplastic cells in urine cytology using BD SurePath™ as preparation method.
Cytology
Ki-67
immunocytochemistry
p16
urine
urothelial carcinoma
Journal
CytoJournal
ISSN: 0974-5963
Titre abrégé: Cytojournal
Pays: United States
ID NLM: 101231642
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
03
2019
accepted:
11
07
2019
entrez:
4
1
2020
pubmed:
4
1
2020
medline:
4
1
2020
Statut:
epublish
Résumé
The objective of this study was to investigate the expression of Ki-67/p16 in urothelial cells in cytological material. There were 142 urines including normal controls, anonymous rest urine, controls after treatment for urothelial carcinoma (UC) and newly diagnosed UC. Immunocytochemistry for ki-67/p16 dual staining kit was performed on all specimens. Eight high-grade UC and six anonymous specimens showed dual positivity. None of the low-grade UC or the control specimens after treated UC showed dual staining. Fifteen of 84 (17.8%) symptomatic cases were negative for both markers, and 59/84 (70.2%) showed positivity for both but not dual staining. Twenty-seven of 84 cases were positive for either Ki-67 ( Co-expression of p16/Ki-67 in the same cells was found in 16.6% of the cases. All were high grade, and co-expression seems to have limited practical impact as an additional marker in urine cytology. Any positivity for p16 alone strongly indicates malignancy. Negative p16 accompanied by a positive Ki-67 rate at 5% or more could be considered as an additional marker for further clinical follow-up. Both markers, co-expressed and separate, can give additional information in follow-up patients after treatment for UC.
Identifiants
pubmed: 31897084
doi: 10.4103/cytojournal.cytojournal_9_19
pii: CJ-16-26
pmc: PMC6909589
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26Informations de copyright
Copyright: © 2019 Sauer, et al.; Licensee Cytopathology Foundation Inc.
Déclaration de conflit d'intérêts
The basis of this article was the master thesis of KM Østbye. The thesis originates from the Oslo Metropolitan University (Oslo, Norway) and was published in Norwegian in 2017. The thesis was rewritten as a research article in English for international publication in Cytojournal. Apart from the above all three authors declare that they have no conflicts of interest.
Références
Cancer Cytopathol. 2017 Jul;125(7):552-562
pubmed: 28371465
Diagn Cytopathol. 2012 Nov;40(11):1019-34
pubmed: 21710648
BMC Cancer. 2017 Apr 7;17(1):247
pubmed: 28388880
Oncogene. 2011 May 5;30(18):2087-97
pubmed: 21297668
Cytopathology. 2016 Apr;27(2):83-90
pubmed: 25580773
Am J Clin Pathol. 2009 Nov;132(5):776-84
pubmed: 19846821
PLoS One. 2014 Apr 21;9(4):e95724
pubmed: 24752337
Cytojournal. 2010 Dec 31;7:24
pubmed: 21298022
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Cancer Cytopathol. 2013 Jun;121(6):320-8
pubmed: 23364848
Cancer Cytopathol. 2012 Aug 25;120(4):276-82
pubmed: 22419364
Diagn Cytopathol. 1997 Aug;17(2):127-33
pubmed: 9258620
Cytojournal. 2010 Oct 11;7:21
pubmed: 20976182
Diagn Cytopathol. 1996 Jul;15(1):78-83
pubmed: 8807259
Adv Anat Pathol. 2008 Sep;15(5):279-86
pubmed: 18724101
Cytopathology. 2013 Oct;24(5):327-34
pubmed: 23003335
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Cytojournal. 2016 Nov 16;13:27
pubmed: 27994636
Cancer Cytopathol. 2013 Oct;121(10):591-7
pubmed: 23801650
Cytopathology. 2014 Feb;25(1):27-38
pubmed: 23461719
J Am Soc Cytopathol. 2015 Mar - Apr;4(2):90-97
pubmed: 31051715
Urol Oncol. 2008 Nov-Dec;26(6):646-51
pubmed: 18367109
Nature. 2006 Sep 28;443(7110):421-6
pubmed: 16957735
Pathology. 1988 Oct;20(4):320-5
pubmed: 2853860
Cancer Cytopathol. 2016 Nov;124(11):811-819
pubmed: 27508949
Cytopathology. 2016 Dec;27(6):456-464
pubmed: 27873391